Torrent Pharmaceuticals has reported strong financial performance for the quarter and year ended March 31, 2026. The company saw a 42% YoY revenue growth in Q4, driven by robust performance across key markets and the strategic integration of JB Pharma. The board has also recommended a final dividend of ₹9 per equity share and approved a fundraising plan of up to ₹5,000 crore through various modes to support future growth.
Financial Performance Overview
For the fourth quarter ended March 31, 2026, Torrent Pharmaceuticals reported consolidated revenue of ₹4,197 crore, reflecting a 42% year-over-year growth. The operating EBITDA for the quarter stood at ₹1,356 crore, up by 41% compared to the same period last year. For the full fiscal year FY26, consolidated revenue reached ₹13,980 crore, representing a 21% annual growth, supported by strong performance in both domestic and international operations.
Strategic Acquisition of JB Pharma
A key highlight of the year was the successful acquisition of a controlling stake in JB Chemicals & Pharmaceuticals (JB Pharma). The company acquired 46.39% of the equity share capital from Tau Investment Holdings Pte. Ltd. on January 21, 2026, and subsequently increased its holding through an open offer and employee acquisitions. This integration has contributed significantly to the financial results for the quarter and is expected to drive further synergies in the coming years.
Shareholder Returns and Fundraising
Reflecting its commitment to shareholder value, the Board has recommended a final dividend of ₹9 per equity share for the financial year. This follows an interim dividend of ₹29 per share paid earlier in the year. Furthermore, to fuel long-term expansion, the company has recommended seeking shareholder approval at the upcoming Annual General Meeting for an enabling resolution to raise funds up to ₹5,000 crore via Qualified Institutional Placement (QIP) or other modes.
Key Geographic Highlights
The company continues to maintain a strong global footprint. In India, base business revenues grew by 15% for the full year, while the US and Brazil businesses recorded impressive growth rates of 24% and 24% respectively for FY26. Despite supply chain challenges, the German market also showed positive momentum with a 10% revenue increase for the fiscal year.
Source: BSE
